euro-obesity-euro-vaccines-2018-tracks

Page 39

Note:

allied

academies

J u n e 2 8 - 2 9 , 2 0 1 8 | A m s t e r d a m , N e t h e r l a n d s

Joint Event on

OBESITY AND WEIGHT MANAGEMENT

VACCINES AND IMMUNOLOGY

International Conference on

Asian Journal of Biomedical and Pharmaceutical Sciences

Volume 8

ISSN:

2249-622X

ASSESSMENT OF THE RISK OF

CONTAMINATION WITH BVD VIRUS

IN PREPARATION OF VETERINARY

RABIES VACCINE

Masoud Ghorbani

and

Narges Norouzzadeh Alinodehi

Pasteur Institute of Iran, Iran

Islamic Azad University, Iran

he absence of contamination is necessary for all veterinary vaccine.

However, the quality control does not always imply that vaccines are

not contaminated. One of the prominent vaccine contaminations is the

presence of a small amount of bovine viral diarrhea virus (BVDV) which

can infect vaccinated animals. In case of preparation of rabies vaccine, the

target animals dogs, and cattle especially in a high-risk environment. The

contamination is sometimes inevitable since the vaccine is prepared in

animal cultured cells that required fetal calf serum (FCS) as well as bovine

serum albumin (BSA). Therefore, a constant quality control is required during

all steps of vaccine preparation to determine the contamination with BVD

virus. We, therefore, carried out

in vitro

experiments to determine the BVDV

using both PCR and ELISA techniques. Samples of tissue culture cells of

five different batches containing fetal calf serum were collected. Randomly,

samples of BSA and FCS used for vaccine preparation were collected as well.

A nested PCR carried out using specific primers for BVDV. An inactivated BVD

virus was used as the positive control. The ELISA test was performed using an

IDEXX BVDV Ag/serum plus kit. Fortunately, neither of RT-PCR or ELISA test

results was positive with BVD virus during all steps of vaccine preparation.

This could be because of both recruiting high-quality reagents and serums

for tissue culture and inactivation of rabies virus with beta-propiolactone

as a recommended agent for viral inactivation. Based on the results of our

experiments, we concluded that a rabies vaccine preparation in our facility is

safe enough for use in cattle as well as other animals.

Masoud Ghorbani has received his Doctor of

Veterinary Medicine degree from the University

of Tehran in 1985 and moved to Ottawa, Ontar-

io, Canada in 1990. He enrolled in his PhD, pro-

gram at the Department of Biochemistry at the

University of Ottawa and was graduated with a

PhD degree. He has extensive experience on de-

veloping innovative peptide and DNA vaccines

against HIV and influenza viruses in animal

models including mice, ferrets, and monkeys

while he was appointed as a Senior Research

Scientist at the Variation Biotechnologies Inc.

in Ottawa, Ontario, Canada. He has also worked

at the Department of Molecular Biology and

Microbiology, Case Western Reserve Universi-

ty, Cleveland, Ohio, USA (2003-2004) as well as

Children’s Hospital of Eastern Ontario, Ottawa,

Canada (CHEO) (2000-2003) as a Senior Re-

search Associate. In 2008, he returned back to

Tehran and started working at Pasteur Institute

of Iran as an Assistant Professor. His current

projects are mainly focused on quality control

of rabies vaccine production as well as the de-

velopment of new version of an oral vaccine for

the use in animals.

mghorbani@irimc.org

BIOGRAPHY

Masoud Ghorbani et al., Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C1-002